(S)-3-(N-tert-butoxycarbonylamine)-3-tert-butylpropanenitrile | 1630982-18-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-3-(N-tert-butoxycarbonylamine)-3-tert-butylpropanenitrile
• 英文别名: (S)-tert-butyl (1-cyano-3-methylbutan-2-yl)carbamate；tert-butyl N-[(2S)-1-cyano-3-methylbutan-2-yl]carbamate
• CAS: 1630982-18-1
• 化学式: C₁₁H₂₀N₂O₂
• 分子量: 212.292
• InChiKey: KNWHKVBSGNXETQ-VIFPVBQESA-N

物化性质

• 沸点：
  333.3±25.0 °C(Predicted)
• 密度：
  0.980±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  62.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-3-(N-tert-butoxycarbonylamine)-3-tert-butylpropanenitrile 在 水 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 生成 S-3-Boc-氨基-4-甲基戊酸
  参考文献：
  名称：

  Protein–Protein Interface Mimicry by an Oxazoline Piperidine-2,4-dione

  摘要：

  Representative minimalist mimics 1 were prepared from amino acids. Scaffold 1 was not designed to mimic any particular secondary structure, but simulated accessible conformations of this material were compared with common ideal secondary structures and with >125,000 different protein-protein interaction (PPI) interfaces. This data mining exercise indicates that scaffolds 1 can mimic features of sheet-turn-sheets, somewhat fewer helical motifs, and numerous PPI interface regions that do not resemble any particular secondary structure.

  DOI：

  10.1021/ol5036547
• 作为产物：
  描述：

  S-3-Boc-氨基-4-甲基戊酸 在 吡啶 、 三聚氯氰 、 二碳酸二叔丁酯 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.17h， 生成 (S)-3-(N-tert-butoxycarbonylamine)-3-tert-butylpropanenitrile
  参考文献：
  名称：

  [EN] TARGETING COMPOUNDS
  [FR] COMPOSÉS DE CIBLAGE

  摘要：

  该披露提供了至少部分针对肝脏、肠道和/或肾脏的化合物，以及它们在治疗肝脏、肠道和/或肾脏疾病中的用途，如非酒精性脂肪肝、酒精性脂肪肝、肝细胞癌、肝硬化和乙型肝炎；和/或慢性肾脏疾病、肾小球疾病，如IgA肾病、狼疮性肾炎或多囊肾病。这些化合物被认为对甲硫氨酰氨肽酶2具有活性。

  公开号：

  WO2019118612A1

文献信息

• [EN] FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME<br/>[FR] COMPOSÉS DE FUMAGILLOL, ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：ZAFGEN INC

  公开号：WO2018031877A1

  公开（公告）日：2018-02-15

  Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  本文披露了富马醇类化合物及其在治疗医学疾病（如肥胖症）中的用途方法。提供了富马醇类化合物的药物组合物和制备方法。这些化合物被认为对蛋氨酸氨肽酶2具有活性。
• Ureidopeptide‐Based Brønsted Bases: Design, Synthesis and Application to the Catalytic Enantioselective Synthesis of β‐Amino Nitriles from (Arylsulfonyl)acetonitriles
  作者：Saioa Diosdado、Rosa López、Claudio Palomo

  DOI：10.1002/chem.201304877

  日期：2014.5.19

  preparation of β‐amino nitriles. We present a highly efficient organocatalytic methodology for the stereoselective synthesis of β‐amino nitriles, in which the key to success is the use of ureidopeptide‐based Brønsted base catalysts in combination with (arylsulfonyl)acetonitriles as synthetic equivalents of the acetonitrile anion. The method gives access to a variety of β‐amino nitriles with good yields

  在亚胺上添加氰基烷基部分是制备β-氨基腈的一种非常有吸引力的方法。我们为立体选择性合成β-氨基腈提供了一种高效的有机催化方法，其中成功的关键是将基于尿素肽的布朗斯台德碱催化剂与（芳基磺酰基）乙腈结合使用作为乙腈阴离子的合成当量。该方法使人们能够以良好的收率和出色的对映选择性获得各种β-氨基腈，并拓宽了可用于合成的立体选择性曼尼希型方法。
• FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME
  申请人：Zafgen, Inc.

  公开号：US20190169181A1

  公开（公告）日：2019-06-06

  Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
• [EN] TARGETING COMPOUNDS<br/>[FR] COMPOSÉS DE CIBLAGE
  申请人：ZAFGEN INC

  公开号：WO2019118612A1

  公开（公告）日：2019-06-20

  The disclosure provides, at least in part, liver, intestine and/or kidney-targeting compounds and their use in treating liver, intestine and/or kidney disorders, such as non-alcoholic steatohepatitis, alcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, and hepatitis B; and/or chronic kidney disease, glomerular disease such as IGA nephropathy, lupus nephritis, or polycystic kidney disease. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  该披露提供了至少部分针对肝脏、肠道和/或肾脏的化合物，以及它们在治疗肝脏、肠道和/或肾脏疾病中的用途，如非酒精性脂肪肝、酒精性脂肪肝、肝细胞癌、肝硬化和乙型肝炎；和/或慢性肾脏疾病、肾小球疾病，如IgA肾病、狼疮性肾炎或多囊肾病。这些化合物被认为对甲硫氨酰氨肽酶2具有活性。
• Protein–Protein Interface Mimicry by an Oxazoline Piperidine-2,4-dione
  作者：Xun Li、Jaru Taechalertpaisarn、Dongyue Xin、Kevin Burgess

  DOI：10.1021/ol5036547

  日期：2015.2.6

  Representative minimalist mimics 1 were prepared from amino acids. Scaffold 1 was not designed to mimic any particular secondary structure, but simulated accessible conformations of this material were compared with common ideal secondary structures and with >125,000 different protein-protein interaction (PPI) interfaces. This data mining exercise indicates that scaffolds 1 can mimic features of sheet-turn-sheets, somewhat fewer helical motifs, and numerous PPI interface regions that do not resemble any particular secondary structure.